13F reference period
Q2 2026
Security Snapshot
Celldex Therapeutics, Inc. - COMMON STOCK (CLDX) Institutional Ownership
CUSIP: 15117B202
13F Institutional Holders and Ownership History from Q4 2018 to Q3 2026
Institutions Reporting
251
Shares (Excl. Options)
85.02M
Full value: 85,016,178 · shares · 30 Jun 2026Price
$37.21
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- CLDX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 85,016,178
- Total 13F value
- $3,163,042,051
- Portfolio coverage rank
- 0.01%
- Share change
- +12,206,798
- Value change
- +$466,276,307
- Number of holders
- 251
- Shares outstanding
- 78,615,935
- SEC-reported price per share
- $32.41
- Insider filing price
- $32.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CLDX - Celldex Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 15117B202.
- 251 institutions reported positions in Q2 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 226 to 251 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$2.31B
Full value: $2,312,964,021 · USD · 31 Mar 2026.$3.16B
Full value: $3,163,042,051 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 251 institutions filings for Q2 2026.
Security key
15117B202
13F reference period
Q2 2026
13F holders
251
13D/G owners
10
CIK / CUSIP context first
Open Q2 2026 holders
CLDX full holder history
Celldex Therapeutics, Inc. SEC filings
Celldex Therapeutics, Inc. company facts
Celldex Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 15117B202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
CLDX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | +85% | $272,538,152 | +$151,072,370 | 8,411,905 | +124% | FMR LLC | 30 Sep 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 12% | +10% | $219,442,153 | +$18,600,852 | 8,079,608 | +9.3% | Wellington Management Group LLP | 31 Dec 2025 |
| BlackRock, Inc. | 7.3% | -12% | $100,867,802 | -$13,842,621 | 4,819,293 | -12% | BlackRock, Inc. | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6% | +60% | $172,357,958 | +$84,722,215 | 4,686,187 | +97% | T. Rowe Price Associates, Inc. | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $109,332,337 | 3,446,795 | Vanguard Capital Management | 31 Mar 2026 | |||
| Commodore Capital LP | 4.6% | -8% | $78,343,026 | -$8,321,474 | 3,028,335 | -9.6% | Commodore Capital LP | 30 Sep 2025 |
| STATE STREET CORP | 4.2% | -18% | $87,658,292 | -$18,554,217 | 2,804,168 | -17% | STATE STREET CORPORATION | 31 Mar 2026 |
| Point72 Asset Management, L.P. | 2.6% | -59% | $43,255,582 | -$66,568,658 | 1,758,357 | -61% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2% | $30,459,938 | 1,356,186 | Eventide Asset Management, LLC | 30 Jun 2025 | |||
| Bellevue Group AG | 1.5% | -78% | $37,512,000 | -$75,576,333 | 1,200,000 | -67% | Bellevue Group AG | 31 Mar 2026 |
As of 30 Jun 2026,
251
institutional investors reported holding
shares of
Celldex Therapeutics, Inc. - COMMON STOCK (CLDX).
This represents
108%
of the company’s total
outstanding shares.
85.02M
Full value: 85,016,178 · shares · 30 Jun 202678.62M
Full value: 78,615,935 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
79%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 12% | 9,543,671 | +11% | 0.06% | $355,119,999 |
| BlackRock, Inc. | 8.9% | 7,002,530 | +30% | 0% | $260,564,141 |
| Kynam Capital Management, LP | 6.8% | 5,322,908 | -8.9% | 11% | $198,065,407 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6% | 4,685,223 | +125% | 0.02% | $174,338,000 |
| STATE STREET CORP | 5% | 3,900,427 | +39% | 0% | $145,134,889 |
| FMR LLC | 4.7% | 3,722,888 | -0.7% | 0.01% | $138,528,663 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 3,464,831 | +17% | 0% | $128,926,362 |
| Deep Track Capital, LP | 3.7% | 2,939,151 | +129% | 1.6% | $109,365,809 |
| Logos Global Management LP | 2.7% | 2,100,000 | +367% | 3.4% | $78,141,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 2,022,226 | +20% | 0% | $75,262,712 |
| Eversept Partners, LP | 2.3% | 1,785,941 | -0.12% | 3.6% | $66,454,865 |
| GOLDMAN SACHS GROUP INC | 2.1% | 1,615,343 | +63% | 0.01% | $60,106,913 |
| Commodore Capital LP | 1.7% | 1,350,000 | -50% | 3% | $50,233,500 |
| Bellevue Group AG | 1.5% | 1,200,000 | 0% | 0.94% | $44,652,000 |
| BAKER BROS. ADVISORS LP | 1.5% | 1,182,611 | +78% | 0.22% | $44,004,955 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 1,170,787 | -6.6% | 0.03% | $43,564,984 |
| DIMENSIONAL FUND ADVISORS LP | 1.4% | 1,073,985 | +1.4% | 0.01% | $39,964,295 |
| AMERICAN CENTURY COMPANIES INC | 1.3% | 1,042,395 | +22% | 0.02% | $38,787,594 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 1,037,000 | 0% | 0.52% | $38,586,770 |
| NOVO HOLDINGS A/S | 1.3% | 1,025,000 | -15% | 2.2% | $38,140,250 |
| Elmind Capital, LP | 1.3% | 990,000 | +14% | 9.3% | $36,837,900 |
| Driehaus Capital Management LLC | 1.3% | 989,442 | 0.21% | $36,817,137 | |
| Fisher Asset Management, LLC | 1.3% | 985,677 | -2.8% | 0.01% | $36,677,040 |
| Pictet Asset Management Holding SA | 1.2% | 917,408 | -0.68% | 0.03% | $34,136,752 |
| Foresite Capital Management VI LLC | 1.1% | 879,713 | +178% | 5.1% | $32,734,121 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
32
Headline period
Q2 2026
Rows shown
1-25 of 32
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,229,065 | $39,781,091 | -$8,624,811 | $32.41 | 29 |
| 2026 Q2 | 85,016,178 | $3,163,042,051 | +$466,276,307 | $37.21 | 251 |
| 2026 Q1 | 72,942,328 | $2,312,964,021 | -$8,940,340 | $31.72 | 226 |
| 2025 Q4 | 73,373,426 | $1,992,600,154 | +$45,987,039 | $27.16 | 184 |
| 2025 Q3 | 70,729,708 | $1,829,814,017 | -$41,022,042 | $25.87 | 180 |
| 2025 Q2 | 72,686,329 | $1,479,214,886 | -$18,971,957 | $20.35 | 178 |
| 2025 Q1 | 73,628,376 | $1,336,550,222 | -$25,518,368 | $18.15 | 170 |
| 2024 Q4 | 73,686,767 | $1,861,792,917 | -$10,935,353 | $25.27 | 172 |
| 2024 Q3 | 71,809,989 | $2,440,639,326 | +$62,002,971 | $33.99 | 174 |
| 2024 Q2 | 69,594,154 | $2,575,716,559 | +$1,332,092 | $37.01 | 181 |
| 2024 Q1 | 69,311,318 | $2,908,781,828 | +$362,625,073 | $41.97 | 196 |
| 2023 Q4 | 60,989,057 | $2,418,831,729 | +$410,573,840 | $39.66 | 162 |
| 2023 Q3 | 50,572,705 | $1,391,763,899 | +$5,531,719 | $27.52 | 140 |
| 2023 Q2 | 50,188,683 | $1,702,972,802 | +$19,493,416 | $33.93 | 148 |
| 2023 Q1 | 49,503,692 | $1,779,547,358 | +$24,122,749 | $35.98 | 158 |
| 2022 Q4 | 48,677,430 | $2,169,609,749 | -$9,316,822 | $44.57 | 163 |
| 2022 Q3 | 49,338,461 | $1,386,923,833 | +$32,333,656 | $28.11 | 146 |
| 2022 Q2 | 48,218,738 | $1,300,004,065 | -$45,672,202 | $26.96 | 146 |
| 2022 Q1 | 49,602,527 | $1,689,417,077 | +$106,143,717 | $34.06 | 157 |
| 2021 Q4 | 46,338,765 | $1,790,195,856 | +$97,400,922 | $38.64 | 170 |
| 2021 Q3 | 43,227,306 | $2,333,703,184 | +$430,296,249 | $53.99 | 156 |
| 2021 Q2 | 35,559,554 | $1,189,106,240 | +$60,325,552 | $33.44 | 127 |
| 2021 Q1 | 34,503,199 | $709,497,850 | -$40,255,166 | $20.60 | 109 |
| 2020 Q4 | 36,816,222 | $645,045,236 | +$72,177,637 | $17.52 | 120 |
| 2020 Q3 | 32,156,087 | $476,873,776 | +$67,764,471 | $14.83 | 82 |